Kornimate/medical-research-clean huggingface dataset:
latent aging mechanisms in pain and sleep

Conditions: Chronic Pain

Summary: chronic pain is a serious public health problem in older adults depending on the pain condition, and the capacity to sleep properly changes with age. given the potential mechanistic role of gaba (gamma-aminobutyric acid) in both conditions, based on our preliminary data, this proposal will determine the effect of oral gaba administration in sleep quality and pain in older adults with chronic pain and sleep disorders as well as to characterize the potential neurobiological mechanisms involved in both illnesses.


Eligibility criteria:
inclusion criteria: * older adults 45 years of age or older who experienced pain of at least moderate intensity (\>5/10 pain intensity ratings) on more days than not during the past three months, and who also reported poor sleep quality (\>5 psqi scores) will be considered for participation. exclusion criteria: 1. serious psychiatric conditions (e.g., schizophrenia, major depression, bipolar disorder; 2. history of alcohol/drug abuse; 3. alzheimer, parkinson, epilepsy and other known intra-cerebral pathology and neurological conditions; 4. significant cognitive impairment as evidenced by the modified mini-mental state examination \[3ms\] score ≤ 77; 5. hospitalizations for mental health reasons in the past year; 6. chronic/current use of narcotic medications; 7. serious systemic (uncontrolled diabetes self-reported ha1c\>7), (uncontrolled hypertension \> 155/90 mm hg) and rheumatic disorders (i.e., rheumatoid arthritis, systemic lupus erythematosus, fibromyalgia, hiv); 8. arterial hypotension; 9. digestive tract diseases; 10. major medical surgery in the past two months, history of brain surgery or any serious brain condition like aneurysm, stroke, or seizures; 11. excessive anxiety regarding protocol procedures; 12. inability to consent for study participation; 13. ingestion of sleep medications including those with zolpidem (ambien and others) and eszopiclone (lunesta and others); 14. neuropathic pain medications including anticonvulsants and antidepressants; 15. allergies or sensitivity to gaba or its ingredients cellulose' gelatin (capsule)' magnesium silicate' vegetable stearate and silica or to the placebo or its ingredients: calcium laurate, hypromellose capsule, magnesium (citrate), microcrystalline cellulose; 16. currently taking barbiturate and benzodiazepine and baclofen; 17. mri contraindications including large pieces of metal in the body/face/neck and claustrophobia; 18. current cancer diagnosis unless determined no evidence of disease or in remission for at least two years, and 19. pregnancy
establishment and application of a new imaging system for otology based on ultra-high resolution ct

Conditions: Hearing Loss; Tinnitus; Vertigo

Summary: tinnitus, hearing loss and vertigo are the three major diseases of otology, affecting hundreds of millions of people in our country, and are major health problems. ear structures and lesions are deeply embedded in the bone, and ct is the preferred examination technique. the key structures of the ear are small and the lesions are hidden. spiral ct is "not visible" and "undiagnosed" due to insufficient spatial resolution. the ultra-high-resolution ct independently developed by our team has a spatial resolution of 50 μm, which is 6 times higher than that of high-end spiral ct, and solves the problem of "not showing" ear diseases. however, with the transformation of imaging modes and the improvement of display capabilities, the imaging system of helical ct is no longer applicable. it is urgent to carry out systematic research to create matching imaging plans, imaging anatomy standards and disease assessment standards to solve the problem of "undiagnosed". problem. this project plans to build an adult and pediatric imaging solution based on ultra-high-resolution ct to optimize image quality and radiation dose; comprehensively evaluate conduction, sensory, and surgical-related fine structures of the ear, and establish a new 0.1mm-scale image anatomy atlas; a prospective study conducted by the center analyzes the hidden pathological changes of tinnitus, deafness and vertigo, evaluates the diagnostic efficacy of ultra-high-resolution ct for the above diseases, and establishes new diagnostic criteria for lesion detection, symptom correlation, and efficacy evaluation. this project will bring new changes to the practice of otology clinical diagnosis and treatment


Eligibility criteria:
1. for healthy volunteers inclusion criteria: * meet the ethical requirements of u-hrct examination * can cooperate to complete u-hrct examination * there is no relevant medical history in the side ear scanned exclusion criteria: * clinical symptoms related to middle and inner ear lesions, such as conduction deafness, sensorineural hearing loss, mixed deafness, vertigo, etc. * congenital inner ear malformation * diseases causing bone changes around the middle and inner ear, such as otitis media, tumors , otosclerosis, fibrous dysplasia, etc. * history of previous ear surgery and trauma * ct image artifacts or incomplete scan coverage * incomplete clinical data 2. for patients with otological diseases inclusion criteria: * due to tinnitus/deafness/peripheral vertigo/peripheral facial paralysis in the ent department of our hospital * meet the ethical requirements of u-hrct examination * can cooperate with the completion of u-hrct examination * surgery in the ent department of our hospital * at least one follow-up or re-examination after discharge exclusion criteria: * history of previous ear surgery and trauma * ct image artifacts or incomplete scanning coverage * incomplete clinical data

Keywords: otology medical imaging tomography, x-ray diagnosis resolution
p53 immunohistochemistry abnormal staining in endometrial cancer

Conditions: Endometrial Cancer

Summary: objective: calculate the incidence of p53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types and grading. patients and methods: 100 cases of endometrial cancer will be included in the study, recruited from alexandria university hospital gyne-oncology unit. surgical staging, histopathological examination and immunohistochemistry of p53 were done to all cases to calculate the incidence of p53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types, grading. keywords: p53 immunohistochemistry, endometrial cancer, clinicopathological relation.


Eligibility criteria:
inclusion criteria: * endometrial cancer patients exclusion criteria: * patients unfit for surgery
the effect of neurodynamic mobilization exercise on lower limb pain in patients with rheumatoid arthritis.

Conditions: Rheumatoid Arthritis

Summary: this clinical trial is the first study to apply neurodynamic mobilization, a nervous system specific therapeutic exercise, on patients with rheumatoid arthritis(ra). objective of the study is to find out the effect of neurodynamic mobilization for joint inflammation in patients with ra.

rheumatoid arthritis (ra) is a chronic autoimmune disorder characterized by generalized joints inflammation. with increasing investigation on the pathology, the treatment focus on the conditions shifted from a musculoskeletal point of view to a systemic approach. the awareness of holistic treatment was also increased. latest studies have found out the neurogenic inflammatory mechanism played an important role in the inflammatory process of ra, the pathological changes of neural tissues in ra were also noted. this clinical trial is the first study to apply neurodynamic mobilization, a nervous system specific therapeutic exercise, on patients with ra. objective of the study is to find out the effect of neurodynamic mobilization for joint inflammation in patients with ra. population adults who are diagnosed with rheumatoid arthritis. intervention neurodynamic exercise comparison standard conservative physiotherapy protocol outcome rheumatoid arthritis pain scale (raps) c-reactive protein (crp) test

Eligibility criteria:
inclusion criteria: * the inclusion criteria was considered as patients with rheumatoid arthritis; presence of inflammatory condition on the joints on upper and / or lower limbs; rheumatoid arthritis pain scale (raps) at least 10 points during activities of daily living; and adults (\> 18 years of age) in either gender. exclusion criteria: * the exclusion criteria are: acute joint pain, physiotherapy or joint injections in the previous 3 months; change in corticosteroids in the previous month; and change in disease-modifying antirheumatic drugs in the previous 3 months; subjects with poor balance or significant pain which neurodynamic mobilization is unable to perform.
preventing malnutrition among older adults

Conditions: Malnutrition

Summary: this project aims to explore whether access to a digital education video can improve the nutritional situation of home-living older adults after being discharged from the hospital.


Eligibility criteria:
inclusion criteria: * orthopedic and surgical in bedded patient patients in a selected regional hospital in norway. * over 65 years old. have their home address in one of nine selected municipalities in nordland county. * home living and due to return home after discharge directly from the hospital or after a short-term training stay at a training centre before returning home. * could read and understand norwegian. * have consent competence. * have a body mass index less than 24. exclusion criteria: * patients patients only receiving liquid diet such as tube feeding * terminal-ill patients

Keywords: older adults disease-related malnutrition educational video
the validity of kleinhauer betke in women with known hemoglobinopathy for fetal-maternal hemorrhage

Conditions: Fetal-Maternal Hemorrhage

Summary: the aim of this study is to determine the validity of kleinhauer betke in women with known hemoglobinopathy for fetal-maternal hemorrhage.


Eligibility criteria:
inclusion criteria: * pregnant with singleton fetus * gestational age 34-42 * with or without known hemoglobinopathy exclusion criteria: * known risk factor for fetal maternal hemorrhage
optimising infliximab induction therapy for acute severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to identify whether an accelerated or intensified infliximab induction regimen is superior to standard induction in acute severe ulcerative colitis in an open label multi-centre randomised controlled trial.


Eligibility criteria:
inclusion criteria: * age \>18 years old * diagnosis of ulcerative colitis * acute severe colitis according to the truelove and witt's criteria * steroid refractory according to the oxford criteria exclusion criteria: * participant unable to consent for themselves * indication for immediate surgery (acute abdomen, perforation of the bowel, haemorrhage) * crohn's disease * participants with enteric infection confirmed on stool microscopy, culture or toxin * haemodynamic instability (mean arterial pressure \<60) and not responsive to fluids * participants with clinically significant cytomegalovirus infection (positive inclusion bodies, immunohistochemistry and signs of viraemia such as fever and abnormal liver function tests) * participants who are pregnant or currently breast-feeding * participants with current malignancy, excluding basal cell carcinoma * participants with flat low or high grade colonic dysplasia; sporadic adenomas permitted * participants with serious co-morbidities including: immunodeficiency; myocardial infarction or acute stroke within the last 3 months; moderate or severe heart failure (new york heart association class iii or iv); active or suspected tuberculosis; renal failure; hepatic failure; other severe infections * participants with history of hypersensitivity to infliximab or infliximab biosimilar * participants who have received other immunosuppressive agents including but not limited to: anti-tnf therapies within 3 months of screening (infliximab, infliximab biosimilar, golimumab, etanercept, certolizumab or adalimumab); anti-integrins (vedolizumb, etrolizumab) within 4 months of screening; calcineurin inhibitors (cyclosporine, tacrolimus) within 4 weeks of screening; t or b cell depleters (rituximab, alemtuzumab) within 12 months of screening; other investigational agents (eg. ustekinumab) within 6 months of screening

Keywords: acute severe ulcerative colitis steroid refractory ulcerative colitis
effect of eliminating gastric residual volume monitoring on ventilator associated events

Conditions: Ventilator Associated Pneumonia

Summary: the aims of this study are to investigate the effect of eliminating routine grv monitoring on vaes in patients receiving mv and early ef, determine the effect of eliminating routine grv monitoring on nutritional adequacy in patients receiving mv and early ef and evaluate the effect of eliminating routine grv monitoring on feeding intolerance in patients receiving enteral feeding.

early enteral nutrition (en) is consistently recommended as first line nutrition therapy in critically ill patients since it favorably alters outcome, providing both nutrition and non-nutrition benefits. however, critically ill patients receiving mechanical ventilation (mv) are at risk for regurgitation, pulmonary aspiration, and eventually ventilator-associated pneumonia (vap). en may increase these risks when gastrointestinal (gi) dysfunction is present. gastric residual volume (grv) is considered a surrogate parameter of gi dysfunction during the progression of enteral feeding in the early phase of critical illness and beyond. about 62% of critically ill patients receive enteral nutrition (en) and in patients on mv, enteral feeding was connected to a threefold increase in the development of vap. a new surveillance definition of ventilator-associated events (vae) was introduced by the national healthcare safety network (nhsn) in 2013 to identify patients who develop complications of mv. it outlines the various events in a step-by-step fashion, beginning with ventilator-associated complications (vac), moving on to infectious complications (ivac), and finally vap. according to the nhsn, vaes occur within 9% to 40% of mechanically ventilated patients

Eligibility criteria:
inclusion criteria: * adults (aged≥18 years) * newly admitted mechanically ventilated patients who are attached to a mechanical ventilator for at least 48 hours. * starting enteral nutrition via a nasogastric tube within 36 hours after intubation. exclusion criteria: * abdominal surgery within the past month. * history of esophageal, duodenal, pancreatic, or gastric surgery. * bleeding from the esophagus, stomach, or bowel. * enteral nutrition via a jejunostomy or gastrostomy. * pregnancy
effect of botulinum toxin on muscles of children with cerebral palsy

Conditions: Cerebral Palsy

Summary: cerebral palsy (cp) is a group of non-progressive motor dysfunction but often changing, secondary to injury or brain abnormalities that occur in early stages of development. in children with cp, the brain injury lead to a delayed motor development in the first weeks, associated with muscular spasticity. drug treatments include oral treatments (baclofen and tizanidine) and injectable treatments like botox (intramuscular injection) and neurolysis with alcohol or phenol (local injection into the nerve). regarding botulinum toxin, there is no study questioning its effectiveness. however, no publication on the pathophysiology of human muscle of the cp child after toxin injection was found. the action of the toxin on the neuromuscular junction (nmj) and muscle structure is unknown in children with cp. the primary objective of this study is to describe structural abnormalities of the cp child's muscle following multiple toxin injections in terms of nmj fragmentation and axonal sprouting. secondary objectives: to evaluate the relationship between: * the severity of the motor impairment and muscle structural abnormalities. * the clinical measure of spasticity and muscle structural abnormalities. * to compare the structure spastic muscles with toxin injections and spastic muscle without toxin injections for muscles with multiple toxin injections, assessing the relationship between : * the number of toxin injections and muscle structural abnormalities. * the date of the first injection and muscle structural abnormalities. * the total dose of injected toxin in the muscle and its structural abnormalities. * the nature of the product injected in the muscle and its structural abnormalities. this innovative study will improve the knowledge on the effects of long-term botulinum toxin injections on the muscle (and therefore its safety in usual care), on the spastic muscle nmj of cp children, on the pathophysiology of the cp child's muscle. all the visits all acts will be performed according to usual patient follow-up. only a biopsy will be performed in addition, taken from an injected muscle during a planned operation. a biopsy may also be performed on a muscle without toxin injection if the act is made possible by the planned surgery. no biopsy will be made on a muscle that would not require surgery.


Eligibility criteria:
inclusion criteria: * age children \> 7 years and \<18 years * with spastic cerebral palsy (all grades of the combined gmfcs * having an orthopedic surgical indication already planned on the lower limbs * receiving toxin injections * with social security coverage * whose parents / holders of parental authority have signed the consent form exclusion criteria: * patients with an evolutive cp * children with a baclofen pump * children who underwent neurotomy or functional dorsal rhizotomy, or alcohol or phenol injections

Keywords: cerebral palsy children muscle spasticity botulinum toxin injection
automatic segmentation ultrasound-based radiomics technology in diabetic kidney disease

Conditions: Diabetic Kidney Disease

Summary: diabetic kidney disease is a common complication of diabetes and the main cause of end-stage renal disease. in this study, the investigator plan to enroll nearly 500 participant with/without dkd and to develop an automatic segmentation ultrasound based radiomics technology to differentiating participant with a non-invasive and an available way.

ultrasound examination is a convenient, cheap and non-invasive method for kidney examination. however, the ability of conventional ultrasound to distinguish diabetic kidney disease from normal kidney is limited, and it is difficult to accurately distinguish between diabetic kidney disease and normal kidney only with the naked eye. in recent years, computer science has developed rapidly and artificial intelligence has been developing continuously. much progress has been made in applying artificial intelligence in data analysis. machine learning is a direction of generalized artificial intelligence, its main characteristic is to make the machine autonomous prediction and create algorithm, so as to achieve autonomous learning. kidney disease and deep learning are two different approaches in the field of machine learning. in this study, image omics and deep learning were used to analyze the images. image omics extracts traditional image features, including shape, gray scale, texture, etc., and uses machine learning (pattern recognition) models to classify and predict, such as support vector machine, random forest, xgboost, etc. deep learning directly uses the convolutional network cnn to extract features, and completes classification and prediction in combination with the full connection layer, etc. this study aims to explore the detection of diabetic kidney disease and its pathological degree based on automatic segmentation ultraound-based radiomics technology, mining of internal information of ultrasound images, and form a set of non-invasive monitoring of diabetic kidney disease complications development system, especially in primary medical institutions, has a broad clinical application prospect.

Eligibility criteria:
inclusion criteria: * patients with clinical diagnosis of t2dm and dkd were enrolled. * patients with clear b mode ultrasound imaging in both side of kidney (left and right). * no missing value in the vital clinical data such as egfr and uacr. exclusion criteria: * patients with large kidney space occupying disease such as kidney renal cyst and tumor were excluded. * ultrasound images with severe shadow or incomplete kidney border were excluded.

Keywords: diabetic kidney disease ultrasound radiomics deep learning multi-center
brief title : optimized endoscopic submucosal dissection with snaring for colorectal neoplasm

Conditions: Colorectal Neoplasms

Summary: this study is aimed to analyze the outcomes after conventional endoscopic submucosal dissection (esd) and optimized esd with snaring (oesd-s) for colorectal neoplasm that is more than 20 mm in diameter of laterllay spreading tumor or flat elevated lesion without stalk. optimized esd with snaring means submucosal dissection followed by snaring when narrowed circumference of the remained submucosal tissue beneath the lesion is less than 5 mm in diameter with snaring, then resected by using an electric current. the investigators expect optimized esd with snaring can provide more time-saving procedure with comparable en-bloc resection rate and perforation rate, when compared with the conventional esd method.


Eligibility criteria:
inclusion criteria: * colorectal laterally spreading tumor that is more than 20 mm in diameter * other elevated or flat colorectal neoplasm without stalk, that is more than 20 mm in diameter exclusion criteria: * colorectal neoplasms that are proven or suspected to be invaded more than submucosal invasion * colorectal neoplasms that have severe fibrosis beneath the target lesion * patient's refusal to participate this study * less than 18 years old * subjects who cannot consent voluntarily due to the communication difficulty
the efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa

Conditions: Epidermolysis Bullosa

Summary: the purpose of this study is to assess the efficacy of trimethoprim in promoting wound healing and decreasing blister formation in patients with epidermolysis bullosa.

epidermolysis bullosa (eb) comprises a series of hereditary disorders characterized by fragility of the skin and mucous membranes and the tendency of the skin to blister in response to minor friction or trauma. the care of patients with eb is a complex task that has to be carried out by a multi-professional team. in the absence of a cure, the goal of therapy is the prevention and healing of chronic wounds. in patients with eb, chronic inflammation interferes with proper wound healing. one treatment option is the use of anti-inflammatory antimicrobial agents, such as trimethoprim, to hasten wound healing and decrease blister formation. this treatment may lead to decreased pain and improvement of the quality of life for these patients.

Eligibility criteria:
inclusion criteria: * patients younger than 20 years of age * diagnosis of recessive dystrophic epidermis bullosa (rdeb)or junctional epidermis bullosa (jeb) * signed consent/assent form exclusion criteria: -previous known allergy or intolerance to trimethoprim

Keywords: pediatrics epidermolysis bullosa trimethoprim wound healing